MetaCap

Insulet Quarterly Income Statement

NASDAQ: PODDHealth CareMedical/Dental InstrumentsUSD

135.28+0.81 (+0.60%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Insulet revenue and earnings

In the quarter ended Jun 30, 2026, Insulet generated $801.7 million in revenue, up 23.5% from the same quarter a year earlier. Net income was $95.0 million (+322.2% year over year), for a net margin of 11.8% versus a median of 12.0% in the prior 5 quarters. Gross margin was 70.2% (up from 69.7%) and operating margin 16.2%.

Diluted earnings per share came in at $1.37, up from $0.32.

Summary generated from market data by MetaCap's automated system. Methodology

Insulet income statement (quarterly)

Insulet quarterly income statement
Quarter (USD)Q2 20262026-06-30Q1 20262026-03-31Q4 20252025-12-31Q3 20252025-09-30Q2 20252025-06-30Q1 20252025-03-31Q4 20242024-12-31Q3 20242024-09-30Q2 20242024-06-30Q1 20242024-03-31Q4 20232023-12-31Q3 20232023-09-30
Revenue801.70M761.70M783.80M706.30M649.10M569.00M597.50M543.90M488.50M441.70M509.80M432.70M
Revenue growth (YoY)+23.51%+33.87%+31.18%+29.86%+32.88%+28.82%+17.20%+25.70%+23.20%+23.35%+37.90%+26.97%
Cost of Revenue239.10M232.70M215.20M196.20M196.90M159.90M166.60M166.80M157.60M134.90M148.60M139.40M
Gross Profit562.60M529.10M568.60M510.10M452.20M409.00M430.90M377.10M330.90M306.80M361.20M293.30M
Operating Expenses432.90M407.00M422.30M392.40M331.10M320.20M321.60M289.00M276.40M249.90M254.70M238.50M
Research & Development88.10M89.70M90.90M77.20M73.40M59.60M60.60M54.90M53.90M50.20M42.00M57.80M
Selling, General & Admin344.80M317.20M331.40M315.20M257.70M260.70M260.90M234.10M222.50M199.70M212.70M180.70M
Operating Income129.70M122.10M146.30M117.70M121.10M88.80M109.30M88.10M54.50M56.90M106.50M54.80M
Interest Expense13.50M14.70M14.90M15.60M19.60M9.20M8.60M12.40M11.00M10.70M6.70M10.40M
Other Income (Expense)-1.10M700.00K3.10M12.10M1.30M-2.20M400.00K-3.40M-1.80M-700.00K1.90M700.00K
Pretax Income118.70M113.00M140.20M122.80M28.40M48.20M111.40M82.90M51.10M54.90M107.90M53.70M
Income Tax23.70M21.90M38.50M35.20M5.90M12.70M10.70M5.40M-137.50M3.40M4.50M1.80M
Net Income95.00M91.10M101.60M87.60M22.50M35.40M100.70M77.50M188.60M51.50M103.30M51.90M
Net Income growth (YoY)+322.22%+157.34%+0.89%+13.03%-88.07%-31.26%-2.52%+49.33%+590.84%+116.39%+507.65%—
EPS (Basic)1.371.301.451.240.320.501.431.112.690.741.490.74
EPS (Diluted)1.371.301.421.240.320.501.381.082.590.731.470.74
Shares Outstanding (Basic)69.30M69.99M—70.37M70.39M70.27M—70.12M70.06M69.96M—69.82M
Shares Outstanding (Diluted)69.40M70.20M—70.66M70.65M74.11M—73.95M73.80M73.74M—73.62M
EBITDA156.40M148.30M170.70M139.70M143.40M110.50M130.80M109.40M73.70M75.70M125.30M73.50M
Gross Margin70.18%69.46%72.54%72.22%69.67%71.88%72.12%69.33%67.74%69.46%70.85%67.78%
Operating Margin16.18%16.03%18.67%16.66%18.66%15.61%18.29%16.20%11.16%12.88%20.89%12.66%
Net Margin11.85%11.96%12.96%12.40%3.47%6.22%16.85%14.25%38.61%11.66%20.26%11.99%

This table shows 12 quarterly periods of Insulet's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PODD's reporting calendar. What is a income statement?

More financial data